The invention compounds of formula (I), their N- oxides, addition salts pharmaceutically acceptable, quaternary amines and stereochemically isomeric forms; Relates to their use, pharmaceutical compositions containing them and methods for their preparation: Wherein Ring A is a 6-membered represents a heterocycle; R ¹ is hydrogen; Aryl; Formyl; C _1-6 alkylcarbonyl; An optionally substituted C _1-6 alkyl; C _1-6 alkyloxycarbonyl; An optionally substituted C _1-6 alkyloxy C _1-6 alkyl-carbonyl, and; X is a bond or a linker atom or group; Z is O or S; R ² is hydrogen, C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, a carbocycle or heterocycle, wherein each group may be optionally substituted; R ³ is hydrogen; Hydroxy; Halo; An optionally substituted C _1-6 alkyl or C _2-6 alkenyl or C _2-6 alkynyl; C _1-6 alkyloxy; C _1-6 alkylthio; C _1-6 alkyloxycarbonyl; C _1-6 alkyl-carbonyl-oxy; Carboxyl; Cyano; Nitro; Amino; Mono- or di (C _1-6 alkyl) amino; C _1-6 alkyl as a poly-to; C _1-6 alkyloxy poly be; C _1-6 alkylthio poly be; R ^21; R ²¹ -C _1-6 alkyl; R ²¹ -O-; R ²¹ -S-; ^{R 21 -C (= O) -} ; _{^{R 21 -S (= O) p}} -; _{^{R 7 -S (= O) p}} -; _{^{R 7 -S (= O) p}} -NH-; _{^{R 21 -S (= O) p}} -NH-; ^{R 7 -C (= O) -} ; -NHC (= O) H; -C (= O) NHNH _2; ^{R 7 -C (= O) -NH-} ; ^{R 21 -C (= O) -NH-} ; -C (= NH) R ^7; -C (= NH) R ²¹ a; R ^4a or R ^4b each independently represents a _{^{hydrogen, R 8, -Y 1 -NR 9}} -Y 2 -NR 10 R 11, -Y 1 -NR 9 -Y 1 -R 8, -Y 1 -NR 9 R 10 ego; However, -XR ² and / or R ³ is not hydrogen.